Table 2.
Most commonly reported adverse events (incidence ≥5% and ≥2 placebo rate in each active treatment group) during 6 weeks of treatment with lurasidone, quetiapine XR, or placebo (safety population)
| Lurasidone 160 mg/d | Lurasidone 80 mg/d | Quetiapine XR 600 mg/d | Placebo | |
|---|---|---|---|---|
| N = 121 | N = 125 | N = 119 | N = 121 | |
| % | % | % | % | |
| Akathisia | 7.4 | 8.0 | 1.7 | 0.8 |
| Parkinsonism | 6.6 | 5.6 | 3.4 | 0 |
| Nausea | 6.6 | 8.0 | 3.4 | 3.3 |
| Dizziness | 5.8 | 4.8 | 13.4 | 1.7 |
| Somnolence | 6.6 | 4.0 | 13.4 | 0.8 |
| Constipation | 0.8 | 2.4 | 6.7 | 2.5 |
| Dry mouth | 1.7 | 1.6 | 7.6 | 0.8 |
| Arthralgia | 0.8 | 1.6 | 5.9 | 0.8 |
| Upper respiratory infection | 0.8 | 1.6 | 5.0 | 0.8 |
| Weight increased | 1.7 | 0.8 | 6.7 | 0.8 |